JESSICA HANNA: Open Payments
NPI 1447903695 · BROUSSARD, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$573 in 36 payments from 12 companies in 2025. Trend: 2023 $572 · 2024 $537 · 2025 $573
Food & beverage: $573
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $137 |
| Amgen Inc. | 6 | $96 |
| Novo Nordisk Inc | 6 | $91 |
| Ardelyx, Inc. | 3 | $55 |
| PFIZER INC. | 3 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| Lilly USA, LLC | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $18 |
Products named: VRAYLAR, OTEZLA, Ozempic, IBSRELA, ELIQUIS, JARDIANCE, QULIPTA, RELISTOR.
Industry payments across LA — which companies pay providers there.
